DOCS

Doximity's stock experienced significant volatility and declines over the past six months, including a 62.98% drop over 12 months and a 43.12% year-to-date decrease as of September 2026. Key events include a 23% decline on May 14, 2026, after missing revenue guidance and providing a cautious outlook, and a 17% fall on February 6, 2026, following lowered fiscal year 2026 revenue guidance. The resignation of CFO Anna Bryson in April 2026 also contributed to leadership uncertainty. Multiple securities fraud class action lawsuits have been initiated, covering August 2024 to May 2026, alleging misleading statements about competitive market share and Newsfeed advertising impact. Despite these challenges, Doximity reported strong fiscal Q1 earnings in early August 2026, beating EPS estimates and showing 7.3% year-over-year revenue growth, leading to some stock rebound. Wolfe Research upgraded shares to 'outperform' in mid-August 2026, and institutional buying interest was noted in September 2026. The company also provided updated revenue guidance for Q2 and fiscal year 2027 and announced a $500 million share repurchase program in February 2026.